Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 23 Sep 2021
Canada should negotiate a fairer share of drug R&D costs
23 September 2021 - Instead of relying on price regulation, Canada should engage in negotiations about drug pricing. ...
Posted by Michael Wonder on 23 Sep 2021
ATAGI statement about the need for additional doses of COVID-19 vaccines
23 September 2021 - A statement from the Australian Technical Advisory Group on Immunisation about the need for COVID-19 vaccine booster ...
Posted by Michael Wonder on 23 Sep 2021
Innovent announces NMPA acceptance of a supplemental new drug application for sintilimab in combination with chemotherapy as first-line therapy for oesophageal squamous cell carcinoma
22 September 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has accepted the supplemental new ...
Posted by Michael Wonder on 23 Sep 2021
FDA authorises booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations
22 September 2021 - Today, the U.S. FDA amended the emergency use authorisation for the Pfizer-BioNTech COVID-19 vaccine to allow ...
Posted by Michael Wonder on 23 Sep 2021
COVID-19 vaccine weekly safety report (23 September 2021)
23 September 2021 - To 19 September 2021, approximately 24.8 million vaccine doses have been given in Australia – 15.1 million ...
Posted by Michael Wonder on 22 Sep 2021
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
21 September 2021 - The WHO Essential Medicines List identifies priority medicines that are most important to public health. Over time, ...
Posted by Michael Wonder on 22 Sep 2021
Pharmaceuticals and Medical Devices Agency's horizon scanning and the Science Board: co-operation toward extracellular vesicle-based products
15 September 2021 - In addition to support academia with regulatory scientific advice, the Pharmaceuticals and Medical Devices Agency' is proactively ...
Posted by Michael Wonder on 22 Sep 2021
NICE terminates yet another appraisal of a medicine for multiple myeloma
22 September 2021 - This is the eleventh terminated appraisal of a medicine for multiple myeloma. London, we have a ...
Posted by Michael Wonder on 22 Sep 2021
Jubilant Radiopharma announces Eckert & Ziegler's GalliaPharm approved for use with NETSpot in Canada
22 September 2021 - Jubilant Radiopharma is the exclusive distributor of GalliaPharm in Canada. ...
Posted by Michael Wonder on 22 Sep 2021
Pfizer CEO rallies staff to fight Democrats' drug price negotiation
22 September 2021 - He added that the company would share methods to raise awareness on the issue in the ...
Posted by Michael Wonder on 22 Sep 2021
FDA approves ruxolitinib for chronic graft-versus-host disease
22 September 2021 - Today the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease after failure ...
Posted by Michael Wonder on 22 Sep 2021
TGA approves Leqvio
22 September 2021 - Inclisiran is a cholesterol lowering double-stranded small interfering ribonucleic acid. ...
Posted by Michael Wonder on 22 Sep 2021
Thousands of Australians waiting for 'gamechanger' cystic fibrosis drug
22 September 2021 - Adelaide woman Genevieve Handley has lived with cystic fibrosis all of her life. ...
Posted by Michael Wonder on 21 Sep 2021
Australia eyes Pfizer’s Covid-19 vaccines for kids aged 5 to 11
21 September 2021 - Australian health officials have confirmed if approved the vaccine would be made widely available to children ...
Posted by Michael Wonder on 21 Sep 2021
bluebird bio submits biologics license application to FDA for betibeglogene autotemcel (beti-cel) gene therapy for patients with β-thalassaemia who require regular red blood cell transfusions
21 September 2021 - Biologics license application submission based on data from Phase 1/2 and Phase 3 Northstar studies, which ...